Clinical Trials Browser

Mid-low Rectal Cancer × tislelizumab × 1 year × Clear all

NCT06333769 2025-08-15

Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer

Phase 2 Completed

Gastrointestinal

Mid-low Rectal Cancer